Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 68
Filter
2.
BMJ Open ; 11(5): e046055, 2021 05 19.
Article in English | MEDLINE | ID: mdl-34011594

ABSTRACT

OBJECTIVES: Little has been reported on the yield and characteristics of colorectal neoplasia detected by the two-sample faecal immunochemical test (FIT), particularly the difference between subjects with two-positive results on the two-sample FIT and those with one-positive results. We aimed to assess risk stratification among patients with positive two-sample FIT to prioritise colonoscopy. DESIGN: A retrospective cross-sectional study. SETTING: A single-centre, representative endoscopy clinic in Japan. PARTICIPANTS: Consecutive patients who underwent colonoscopy were enrolled. Indications for colonoscopy included two-positive results on the two-sample FIT (FIT (+/+)), one-positive results on the two-sample FIT (FIT (+/-)), and other reasons (non-FIT group, including presence of symptoms, screening or surveillance). PRIMARY AND SECONDARY OUTCOME MEASURES: Primary outcomes were detection rates of colorectal cancers, including in situ (all cancers) and invasive cancers, based on the indications for colonoscopy. Secondary outcomes were cancer features, such as location, size, T stage and histological subtype. RESULTS: Of the 8724 patients, 264 underwent colonoscopy following FIT (+/+), 1018 following FIT (+/-) and 7442 for reasons other than positive FIT. Detection rates of all (and invasive) cancers in the FIT (+/+), FIT (+/-) and non-FIT groups were 12.1% (8.3%), 1.9% (0.3%) and 0.4% (0.2%), respectively. The cancer detection rates were much higher in the FIT (+/+) group than in the FIT (+/-) group, which in turn had higher rates than the non-FIT group. Moreover, the FIT (+/+) group showed more advanced T stages on tumour, node, metastasis (TNM) classification (Tis/T1/T2/T3/T4: 10/7/4/10/1) than the FIT (+/-) group (16/1/2/0/0, p<0.001). CONCLUSIONS: Two-positive results for two-sample FIT showed a much higher yield for more advanced colorectal cancers than the one-positive result. High priority for diagnostic colonoscopy should be assigned to patients with two-positive-FIT results.


Subject(s)
Colorectal Neoplasms , Early Detection of Cancer , Colonoscopy , Colorectal Neoplasms/diagnosis , Cross-Sectional Studies , Feces , Humans , Japan/epidemiology , Mass Screening , Occult Blood , Retrospective Studies
3.
Ann Med ; 52(8): 506-514, 2020 12.
Article in English | MEDLINE | ID: mdl-32536216

ABSTRACT

INTRODUCTION: Recent prevalence and trends of gastric/duodenal ulcer (GU/DU) and reflux esophagitis (RE) are inadequate. METHODS: We reviewed the records of consecutive 211,347 general population subjects from 1991 to 2015. RESULTS: During the 25 years, the prevalence of GU and DU has gradually decreased (from 3.0% to 0.3% and from 2.0% to 0.3%) whereas that of RE has markedly increased (from 2.0% to 22%). The prevalence of Helicobacter pylori (HP) infection has decreased from 49.8% (in 1996) to 31.2% (in 2010). Multivariable logistic regression analyses demonstrated that HP infection was positively associated with GU/DU and negatively associated with RE with statistical significance. The panel data analyses showed that reduced rate of HP infection is proportionally correlated with decrease of GU/DU and inversely correlated with increase of RE. It is further suggested other latent factors should be important for changed prevalence of these three acid-related diseases. Age-period-cohort analysis indicated the significant association of older age, male gender, and absence of HP infection with RE. CONCLUSIONS: The prevalence of GU and DU has gradually decreased whereas that of RE has markedly increased in Japan. Inverse time trends of peptic ulcer and reflux esophagitis are significantly associated with reduced prevalence of HP infection. KEY MESSAGES The prevalence of gastric and duodenal ulcer has gradually decreased whereas that of reflux esophagitis has markedly increased in Japan. The prevalence of Helicobacter pylori infection in Japan has greatly decreased from 49.8% to 31.2% during the 14 years (from 1996 to 2010). Inverse time trends of peptic ulcer and reflux esophagitis are associated with reduced prevalence of Helicobacter pylori infection with statistical significance.


Subject(s)
Duodenal Ulcer/epidemiology , Esophagitis, Peptic/epidemiology , Helicobacter Infections/epidemiology , Stomach Ulcer/epidemiology , Adult , Aged , Aged, 80 and over , Antibodies, Bacterial/blood , Antibodies, Bacterial/immunology , Duodenal Ulcer/diagnosis , Endoscopy, Gastrointestinal , Esophagitis, Peptic/diagnosis , Female , Helicobacter Infections/blood , Helicobacter Infections/diagnosis , Helicobacter Infections/microbiology , Helicobacter pylori/immunology , Helicobacter pylori/isolation & purification , Humans , Japan/epidemiology , Male , Middle Aged , Prevalence , Retrospective Studies , Stomach Ulcer/diagnosis , Time Factors , Young Adult
5.
Surg Endosc ; 31(5): 2140-2148, 2017 05.
Article in English | MEDLINE | ID: mdl-27604367

ABSTRACT

BACKGROUND: Risk factors for gastric cancer during continuous infection with Helicobacter pylori have been well documented; however, little has been reported on the risk factors for primary gastric cancer after H. pylori eradication. We conducted a retrospective, endoscopy-based, long-term, large-cohort study to clarify the risk factors for gastric cancer following H. pylori eradication. METHODS: Patients who achieved successful H. pylori eradication and periodically underwent esophagogastroduodenoscopy surveillance thereafter at Toyoshima Endoscopy Clinic were enrolled. The primary endpoint was the development of gastric cancer. Statistical analysis was performed using the Kaplan-Meier method and Cox's proportional hazards models. RESULTS: Gastric cancer developed in 15 of 1232 patients. The cumulative incidence rates were 1.0 % at 2 years, 2.6 % at 5 years, and 6.8 % at 10 years. Histology showed that all gastric cancers (17 lesions) in the 15 patients were of the intestinal type, within the mucosal layer, and <20 mm in diameter. Based on univariate analysis, older age and higher endoscopic grade of gastric atrophy were significantly associated with gastric cancer development after eradication of H. pylori, and gastric ulcers were marginally associated. Multivariate analysis identified higher grade of gastric atrophy (hazard ratio 1.77; 95 % confidence interval 1.12-2.78; P = 0.01) as the only independently associated parameter. CONCLUSIONS: Endoscopic gastric atrophy is a major risk factor for gastric cancer development after H. pylori eradication. Further long-term studies are required to determine whether H. pylori eradication leads to regression of H. pylori-related gastritis and reduces the risk of gastric cancer.


Subject(s)
Helicobacter Infections/epidemiology , Stomach Neoplasms/epidemiology , Stomach/pathology , Atrophy , Endoscopy, Digestive System , Female , Follow-Up Studies , Helicobacter pylori , Humans , Japan/epidemiology , Male , Middle Aged , Retrospective Studies , Risk Factors
6.
Saudi J Gastroenterol ; 22(5): 385-390, 2016.
Article in English | MEDLINE | ID: mdl-27748326

ABSTRACT

BACKGROUND/AIM: The efficacy of flexible spectral imaging color enhancement (FICE) ch. 1 (F1) for the detection of ulcerative lesions and angioectasias in the small intestine with capsule endoscopy (CE) has been reported. In the present study, we evaluated whether F1 could detect incremental findings in patients with no findings in a standard review mode. PATIENTS AND METHODS: In total, 52 patients (age: 60.1 ± 15.3 years; 30 males) with obscure gastrointestinal bleeding (OGIB) who underwent CE and in whom no lesion was detected in the small intestine in the standard mode (first review) were enrolled. Two experienced endoscopists independently reviewed CE videos again by F1 (second review). The following findings were defined to be significant: Ulcers, erosions, aphthas, angioectasias, tumors, and bleeding. Incremental findings at the second review were checked at F1 and in standard mode by the two reviewers (third review). Finally, the findings were confirmed by the agreement of the two reviewers at the third review. RESULTS: F1 detected five significant lesions in three patients with overt OGIB; three erosions, one aphtha, and one angioectasia. For nonsignificant lesions, F1 detected 12 red mucosas and 16 red spots. Moreover, 29 patients with 71 findings were considered false positives. CONCLUSION: F1 detected incremental significant findings in a small percentage of patients with no findings in the standard review mode. In addition, F1 showed many false-positive findings. The incremental effect of a repeated review by F1 in patients with no findings in the first review is limited.


Subject(s)
Capsule Endoscopy/methods , Image Enhancement/methods , Intestinal Diseases/diagnostic imaging , Intestine, Small/pathology , Aged , False Positive Reactions , Female , Gastrointestinal Hemorrhage/etiology , Humans , Male , Middle Aged , Retrospective Studies
7.
Dig Dis Sci ; 61(6): 1677-85, 2016 06.
Article in English | MEDLINE | ID: mdl-26831490

ABSTRACT

BACKGROUND: Both colorectal neoplasms and atherosclerosis can be induced by common visceral fat accumulation. However, the association between these diseases at the advanced stage, colorectal cancer and cardiovascular/cerebrovascular diseases, has not been elucidated. AIMS: This study aimed to investigate the association between colorectal cancer and vascular diseases in relation to obesity and metabolic disorders, using a nationwide database of hospitalized patients in Japan. We used non-cardiac gastric cancer patients as a reference, because they were considered to be neutral for obesity or metabolic disorders. METHODS: We identified 54,591 patients with colorectal cancer and 19,565 patients with gastric cancer from the Diagnosis Procedure Combination database. The data collected included: sex; age; body mass index (BMI); smoking status; comorbidity; and medication data, comprising hypertension, diabetes, hyperlipidemia, coronary artery disease, and stroke. We compared these data in a cross-sectional setting by multivariate analyses. RESULTS: Multivariate logistic regression analyses showed that female sex, increased BMI, hypertension [odds ratio (OR) 1.11; 95 % confidence interval (CI) 1.07-1.15; P < 0.0001], and diabetes (OR 1.17; 95 % CI 1.12-1.23; P < 0.0001) were more associated with colorectal cancer than with gastric cancer. Smoking, aspirin use (OR 0.85; 95 % CI 0.79-0.92; P < 0.0001), and coronary artery disease (OR 0.90; 95 % CI 0.86-0.95; P = 0.0001) were inversely associated with colorectal cancer. CONCLUSIONS: Obesity and metabolic disorders were more associated with colorectal cancer than with non-cardiac gastric cancer, while coronary artery disease (CAD) was inversely associated. Some mechanisms involving separate populations of colorectal cancer and CAD under visceral fat accumulation might be suggested.


Subject(s)
Atherosclerosis/complications , Colorectal Neoplasms/complications , Databases, Factual , Aged , Aged, 80 and over , Atherosclerosis/epidemiology , Colorectal Neoplasms/epidemiology , Female , Humans , Japan/epidemiology , Male , Middle Aged , Retrospective Studies , Risk Factors
8.
BMC Gastroenterol ; 15: 143, 2015 Oct 21.
Article in English | MEDLINE | ID: mdl-26486595

ABSTRACT

BACKGROUND: Helicobacter pylori infection is the most important risk factor for gastric cancer, for which eradication therapy is commonly performed. However, gastric cancer is sometimes discovered after successful eradication of H. pylori. Much evidence indicates that diabetes mellitus (DM) is a risk factor for gastric cancer. The incidence and characteristics of gastric cancer diagnosed after H. pylori eradication in DM patients remain to be determined. METHODS: We followed the clinical course of patients who underwent H. pylori eradication therapy at our institution. Endoscopy was performed before and after eradication. We compared the incidence and clinical characteristics of gastric cancer arising in DM and non-DM patients. RESULTS: In total, 965 patients who underwent successful eradication (518 DM and 447 non-DM patients) were followed-up for an average of 4.5 years. During the follow-up period, 21 gastric cancers were diagnosed (12 in DM patients and 9 in non-DM patients). The incidence of gastric cancer after eradication was not significantly different between DM and non-DM patients (0.485 and 0.482 %/year, respectively). There was no significant difference in the pathology, diameter, depth, location, or treatment of gastric cancer between patients with and without DM. CONCLUSION: The incidence and characteristics of gastric cancer occurring after H. pylori eradication were comparable between DM and non-DM patients.


Subject(s)
Diabetes Complications/epidemiology , Diabetes Mellitus/microbiology , Helicobacter Infections/complications , Helicobacter pylori , Stomach Neoplasms/epidemiology , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Diabetes Complications/microbiology , Female , Follow-Up Studies , Helicobacter Infections/drug therapy , Helicobacter Infections/microbiology , Humans , Incidence , Male , Middle Aged , Risk Factors , Stomach Neoplasms/diagnosis , Stomach Neoplasms/microbiology
9.
J Dig Dis ; 16(11): 649-55, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26356801

ABSTRACT

OBJECTIVE: Patients who take drugs regularly are increasing, not least due to metabolic and orthopedic diseases. In the present study we aimed to investigate the association between the use of drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin, and colorectal polyps diagnosed based on colonoscopic findings. METHODS: In total, 1318 consecutive patients who underwent total colonoscopy for the first time were cross-sectionally analyzed. Personal data including comorbidities and all medications were obtained by a questionnaire. Their blood pressure, body weight and waist circumference were measured just before the colonoscopic examination. RESULTS: Colorectal polyps were found in 577 (43.8%) patients, with a prevalence of 57.6% (296/514) in patients receiving antihypertensive treatment and 35.0% (281/804) in patients not undergoing such treatment. A multivariate analysis showed that age, waist circumference, alcohol consumption, smoking and the use of antihypertensive drugs were independent risk factors for colorectal polyps. In a secondary multivariate analysis incorporating the parameters of measured blood pressure and medication status, the number of antihypertensive drugs was strongly associated with the risk of colorectal polyps, whereas blood pressure showed no significant association. CONCLUSIONS: The use of antihypertensive drug may be a risk factor for colorectal polyps. Furthermore, this risk increases with the intensive use of antihypertensive drugs.


Subject(s)
Antihypertensive Agents/adverse effects , Colorectal Neoplasms/chemically induced , Intestinal Polyps/chemically induced , Aged , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Aspirin/adverse effects , Blood Pressure/physiology , Colonic Polyps/chemically induced , Colonic Polyps/physiopathology , Colonoscopy , Colorectal Neoplasms/physiopathology , Cross-Sectional Studies , Female , Humans , Intestinal Polyps/physiopathology , Male , Middle Aged , Prospective Studies , Risk Factors
10.
Can J Gastroenterol Hepatol ; 29(6): 321-5, 2015.
Article in English | MEDLINE | ID: mdl-26069891

ABSTRACT

BACKGROUND: Endoscopic submucosal dissection (ESD) of early gastric cancer is a minimally invasive procedure. However, the risk for metachronous cancers after successful cancer treatment remains high and the risk factors for metachronous cancers have not been elucidated. OBJECTIVE: To evaluate the risk factors for metachronous gastric cancers after ESD with a long-term follow-up. METHODS: A total of 155 consecutive patients (119 men, 36 women, mean age 68.9 years) were treated with ESD between September 2000 and September 2009. Biopsy specimens were obtained from the greater curvature of the antrum and middle corpus to evaluate gastric mucosal status, including Helicobacter pylori, intestinal metaplasia (IM) and neutrophil infiltration (NI) before ESD. Follow-up endoscopy after ESD was scheduled at two and six months, one year and annually thereafter. H pylori eradication was recommended when possible. RESULTS: The median follow-up period was 4.2 years. Metachronous gastric cancers were found in 23 of 155 patients (3.5% per year). No local recurrences were observed. The cumulative incidence of metachronous gastric cancer was significantly high in IM and NI in the corpus (P=0.0093 and P=0.0025, respectively [log-rank test]). The ORs for IM and NI in the corpus were 2.65 and 3.06, respectively, according to the Cox proportional hazards model (P=0.024 and P=0.0091, respectively). CONCLUSIONS: The presence of IM and NI in the corpus was closely related to the development of metachronous gastric cancer after ESD.


Subject(s)
Dissection/adverse effects , Intestines/pathology , Neoplasms, Second Primary/epidemiology , Neutrophil Infiltration , Stomach Neoplasms/immunology , Aged , Aged, 80 and over , Dissection/methods , Female , Follow-Up Studies , Gastric Mucosa/surgery , Gastroscopy , Helicobacter pylori , Humans , Male , Metaplasia , Middle Aged , Stomach Neoplasms/pathology , Stomach Neoplasms/surgery
11.
World J Gastroenterol ; 21(23): 7242-7, 2015 Jun 21.
Article in English | MEDLINE | ID: mdl-26109811

ABSTRACT

AIM: To investigate visceral fat accumulation in association with the risk of small bowel angioectasia. METHODS: We retrospectively investigated 198 consecutive patients who underwent both capsule endoscopy and CT for investigation of obscure gastrointestinal bleeding (OGIB) from January 2009 to September 2013. The visceral fat area (VFA) and subcutaneous fat area were measured by CT, and information on comorbidities, body mass index, and medications was obtained from their medical records. Logistic regression analysis was used to evaluate associations. RESULTS: Capsule endoscopy revealed small bowel angioectasia in 18/198 (9.1%) patients with OGIB. Compared to patients without small bowel angioectasia, those with small bowel angioectasia had a significantly higher VFA (96 ± 76.0 cm(2) vs 63.4 ± 51.5 cm(2), P = 0.016) and a higher prevalence of liver cirrhosis (61% vs 22%, P < 0.001). The proportion of patients with chronic renal failure was higher in patients with small bowel angioectasia (22% vs 9%, P = 0.11). There were no significant differences in subcutaneous fat area or waist circumference. The prevalence of small bowel angioectasia progressively increased according to the VFA. Multivariate analysis showed that the VFA [odd ratio (OR) for each 10-cm(2) increment = 1.1; [95% confidence interval (CI): 1.02-1.19; P = 0.021] and liver cirrhosis (OR = 6.1, 95%CI: 2.2-18.5; P < 0.001) were significant risk factors for small bowel angioectasia. CONCLUSION: VFA is positively associated with the prevalence of small bowel angioectasia, for which VFA and liver cirrhosis are independent risk factors in patients with OGIB.


Subject(s)
Adiposity , Gastrointestinal Hemorrhage/epidemiology , Intestinal Mucosa/blood supply , Intestine, Small/blood supply , Intra-Abdominal Fat/physiopathology , Obesity/epidemiology , Aged , Capsule Endoscopy , Comorbidity , Dilatation, Pathologic , Female , Gastrointestinal Hemorrhage/diagnosis , Humans , Intra-Abdominal Fat/diagnostic imaging , Japan/epidemiology , Liver Cirrhosis/epidemiology , Logistic Models , Male , Middle Aged , Multivariate Analysis , Obesity/diagnosis , Obesity/physiopathology , Odds Ratio , Prevalence , Retrospective Studies , Risk Factors , Tomography, X-Ray Computed
12.
PLoS One ; 10(4): e0123688, 2015.
Article in English | MEDLINE | ID: mdl-25860671

ABSTRACT

BACKGROUND: Despite the marked increase of diverticulosis, its risk factors have not been adequately elucidated. We therefore aim to identify significantly associated factors with diverticulosis. We also aim to investigate the present state of diverticulosis in Japan. METHODS: We reviewed the medical records from 1990 to 2010 that included the data of consecutive 62,503 asymptomatic colonoscopy examinees from the general population in Japan. Most recent 3,327 examinees were analyzed with 16 background factors. RESULTS: Among the 62,503 subjects (47,325 men and 15,178 women; 52.1 ± 9.2 years old), diverticulosis was detected in 11,771 subjects (18.8%; 10,023 men and 1,748 women). The incidences of diverticulosis in 1990-2000 and 2001-2010 were respectively 13.0% (3,771 of 29,071) and 23.9% (8,000 of 33,432): the latter was much higher than the former in all age groups and for both genders. Considering the anatomical locations of colorectal diverticula, left-sided ones have markedly increased with age but not significantly changed with times. Univariate analyses of the 3,327 subjects showed significant association of diverticulosis with four basic factors (age, sex, body mass index, blood pressure), three life style-related factor (smoking, drinking, severe weight increase in adulthood), and two blood test values (triglyceride, HbA1c). The multiple logistic analysis calculating standardized coefficients (ß) and odds ratio (OR) demonstrated that age (ß = 0.217-0.674, OR = 1.24-1.96), male gender (ß = 0.185, OR = 1.20), smoking (ß = 0.142-0.200, OR = 1.15-1.22), severe weight increase in adulthood (ß = 0.153, OR = 1.17), HbA1c (ß = 0.136, OR = 1.15), drinking (ß = 0.109, OR = 1.11), and serum triglyceride (ß = 0.098, OR = 1.10) showed significantly positive association with diverticulosis whereas body mass index and blood pressure did not. CONCLUSIONS: The large-scale data of asymptomatic colonoscopy examinees from the general population from 1990 to 2010 indicated that the prevalence of diverticulosis is still increasing in Japan. Age, male gender, smoking, severe weight increase in adulthood, serum HbA1c, drinking, and serum triglyceride showed significant positive association with diverticulosis.


Subject(s)
Diverticulum/epidemiology , Adult , Age Factors , Aged , Aged, 80 and over , Alcohol Drinking/adverse effects , Colonoscopy , Diverticulum/etiology , Diverticulum/metabolism , Diverticulum, Colon/epidemiology , Diverticulum, Colon/etiology , Diverticulum, Colon/metabolism , Female , Glycated Hemoglobin/metabolism , Humans , Incidence , Japan/epidemiology , Life Style , Male , Middle Aged , Multivariate Analysis , Prevalence , Rectal Diseases/epidemiology , Rectal Diseases/etiology , Rectal Diseases/metabolism , Retrospective Studies , Sex Factors , Smoking/adverse effects , Triglycerides/blood , Weight Gain , Young Adult
13.
J Gastroenterol Hepatol ; 30(8): 1260-4, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25777777

ABSTRACT

BACKGROUND AND AIM: Helicobacter pylori, gastritis, and intestinal metaplasia (IM) are known risk factors for gastric cancer. In the present study, we conducted a cohort study to evaluate the predictive value of the distribution of IM for gastric cancer development. METHODS: We conducted a retrospective cohort study at a university hospital. From June 1998 to December 2000, we assessed histological gastritis using biopsy specimens, one from the antrum and one from the corpus, from 1450 patients, among whom 729 revisited for follow-up endoscopy. Patients were classified into three groups according to the distribution of IM at initial endoscopy. IM group A had no IM, IM group B had IM in the antrum only, and IM group C had IM in the corpus. The development of gastric cancer was assessed by endoscopic examination. RESULTS: The mean duration of follow-up was 6.7 ± 4.7 years. The cumulative incidence of gastric cancer at 5 years was 1.5% in total and 0.8%, 3.3%, and 2.7% in IM groups A, B, and C, respectively. The IM group was identified as an independent risk factor by multivariate analysis; compared with IM group A, hazard ratios were 3.6 (95% confidence interval [CI] 1.1-12.1) in IM group B and 3.8 (95% CI 1.01-14.1) in IM group C. In IM group C, the incidence of gastric cancer in patients who received eradication therapy was significantly lower than that in patients who did not receive (P = 0.021, log-rank). CONCLUSION: IM is a good predictive marker for the development of gastric cancer.


Subject(s)
Gastritis/complications , Gastritis/microbiology , Helicobacter Infections , Intestines/pathology , Stomach Neoplasms/epidemiology , Stomach Neoplasms/etiology , Aged , Cohort Studies , Female , Follow-Up Studies , Gastritis, Atrophic/etiology , Gastroscopy , Helicobacter pylori , Humans , Incidence , Male , Metaplasia/etiology , Middle Aged , Multivariate Analysis , Predictive Value of Tests , Retrospective Studies , Risk Factors
14.
World J Gastroenterol ; 21(1): 326-32, 2015 Jan 07.
Article in English | MEDLINE | ID: mdl-25574108

ABSTRACT

AIM: To elucidate the association between small bowel diseases (SBDs) and positive fecal occult blood test (FOBT) in patients with obscure gastrointestinal bleeding (OGIB). METHODS: Between February 2008 and August 2013, 202 patients with OGIB who performed both capsule endoscopy (CE) and FOBT were enrolled (mean age; 63.6 ± 14.0 years, 118 males, 96 previous overt bleeding, 106 with occult bleeding). All patients underwent immunochemical FOBTs twice prior to CE. Three experienced endoscopists independently reviewed CE videos. All reviews and consensus meeting were conducted without any information on FOBT results. The prevalence of SBDs was compared between patients with positive and negative FOBT. RESULTS: CE revealed SBDs in 72 patients (36%). FOBT was positive in 100 patients (50%) and negative in 102 (50%). The prevalence of SBDs was significantly higher in patients with positive FOBT than those with negative FOBT (46% vs 25%, P = 0.002). In particular, among patients with occult OGIB, the prevalence of SBDs was higher in positive FOBT group than negative FOBT group (45% vs 18%, P = 0.002). On the other hand, among patients with previous overt OGIB, there was no significant difference in the prevalence of SBDs between positive and negative FOBT group (47% vs 33%, P = 0.18). In disease specific analysis among patients with occult OGIB, the prevalence of ulcer and tumor were higher in positive FOBT group than negative FOBT group. In multivariate analysis, only positive FOBT was a predictive factors of SBDs in patients with OGIB (OR = 2.5, 95%CI: 1.4-4.6, P = 0.003). Furthermore, the trend was evident among patients with occult OGIB who underwent FOBT on the same day or a day before CE. The prevalence of SBDs in positive vs negative FOBT group were 54% vs 13% in patients with occult OGIB who underwent FOBT on the same day or the day before CE (P = 0.001), while there was no significant difference between positive and negative FOBT group in those who underwent FOBT two or more days before CE (43% vs 25%, P = 0.20). CONCLUSION: The present study suggests that positive FOBT may be useful for predicting SBDs in patients with occult OGIB. Positive FOBT indicates higher likelihood of ulcers or tumors in patients with occult OGIB. Undergoing CE within a day after FOBT achieved a higher diagnostic yield for patients with occult OGIB.


Subject(s)
Gastrointestinal Hemorrhage/diagnosis , Intestinal Diseases/diagnosis , Intestine, Small , Occult Blood , Aged , Capsule Endoscopy , Chi-Square Distribution , Female , Gastrointestinal Hemorrhage/epidemiology , Humans , Intestinal Diseases/epidemiology , Intestinal Neoplasms/diagnosis , Intestinal Neoplasms/epidemiology , Intestine, Small/pathology , Japan/epidemiology , Logistic Models , Male , Middle Aged , Multivariate Analysis , Odds Ratio , Predictive Value of Tests , Prevalence , Prognosis , Retrospective Studies , Risk Factors , Time Factors , Ulcer/diagnosis , Ulcer/epidemiology
15.
J Gastroenterol ; 50(5): 533-40, 2015 May.
Article in English | MEDLINE | ID: mdl-25181990

ABSTRACT

BACKGROUND: Bleeding of the lower gastrointestinal tract requires hospitalization and can cause in-hospital death in the most serious cases; however, only a few studies have evaluated in-hospital death from bleeding of the lower gastrointestinal tract. The aim of this study was to investigate the in-hospital mortality of patients with bleeding of the lower gastrointestinal tract and elucidate the factors associated with it using a large-scale database. METHODS: We analyzed a nationwide database in Japan retrospectively. From the Diagnosis Procedure Combination database, we extracted data on patients who were admitted with visible blood in stool between July 1, 2010 and March 31, 2012. We assessed age, sex, comorbidity, cause of bleeding, type of hospital, medications, body mass index (BMI), and need for blood transfusion and treatments. A multivariable logistic regression model was used to examine factors associated with blood transfusion and in-hospital death. RESULTS: A total of 30,846 patients were identified. The median age was 74 years, and 52.0% of patients were male. A total of 782 patients died in hospital (2.5%), and 8,060 patients (26.1%) needed blood transfusion. In a multivariate analysis, in-hospital death was significantly associated with being older or male; comorbidities, including congestive heart failure, renal disease, and mild to severe liver disease; the cause of bleeding; a nonacademic hospital; nonsteroidal anti-inflammatory drug use; lower BMI; and requirements for blood transfusion, interventional radiology, and surgery. Most factors were similarly associated with blood transfusion. CONCLUSIONS: In-hospital mortality was 2.5% and was associated with age, sex, comorbidities, cause of bleeding, type of hospital, nonsteroidal anti-inflammatory drug use, BMI, blood transfusion, and requirements for treatments.


Subject(s)
Gastrointestinal Hemorrhage/diagnosis , Gastrointestinal Hemorrhage/mortality , Hospital Mortality , Inflammatory Bowel Diseases/complications , Inpatients/statistics & numerical data , Age Distribution , Aged , Aged, 80 and over , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Blood Transfusion/statistics & numerical data , Body Mass Index , Databases, Factual , Female , Gastrointestinal Hemorrhage/etiology , Humans , Japan/epidemiology , Length of Stay/statistics & numerical data , Male , Middle Aged , Retrospective Studies , Risk Assessment , Risk Factors , Sex Distribution
16.
Am J Pathol ; 185(2): 550-62, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25478808

ABSTRACT

Small bowel adenocarcinoma (SBA) is a rare, aggressive malignancy with a poor prognosis, and the mechanisms of carcinogenesis in SBA remain unclear. Our aims were to investigate the molecular mechanisms underlying SBA and to identify treatments by establishing and characterizing an SBA cell line and performing anti-cancer drug screening. SIAC1 cells, established from jejunal SBA, showed epithelial characteristics and formed organoids in 3D culture. SIAC1 cells had a heterozygous ß-catenin deletion mutation, resulting in a stable ß-catenin protein with enhanced Wnt/ß-catenin activity. SIAC1 cells lacked MLH1 and MSH6 expression, and target genes such as TGFBR2 and ACVR2 showed frameshift mutations. Among 10 clinical SBA samples, 2 (20%) had interstitial deletions in ß-catenin, expression of mismatch repair protein was aberrant in 4 (40%), and heterozygous frameshift mutations of three target genes were found in all 10 samples. On screening assay using 140 compounds, eribulin significantly inhibited SIAC1 cell growth both in vitro and in vivo by inhibition of the Wnt/ß-catenin pathway via enhanced degradation of ß-catenin. In conclusion, we established an SBA cell line with molecular characteristics similar to those of clinical SBA samples, including ß-catenin deletion and mismatch repair protein deficiency, that will be useful for SBA research. Eribulin might be a candidate for SBA treatment due to its inhibitory effect on Wnt/ß-catenin signaling.


Subject(s)
Activin Receptors, Type II , Adenocarcinoma , Cell Line, Tumor , Frameshift Mutation , Furans/pharmacology , Intestinal Neoplasms , Ketones/pharmacology , Neoplasm Proteins , Protein Serine-Threonine Kinases , Receptors, Transforming Growth Factor beta , Activin Receptors, Type II/genetics , Activin Receptors, Type II/metabolism , Adenocarcinoma/drug therapy , Adenocarcinoma/genetics , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Adult , Aged , Cell Line, Tumor/metabolism , Cell Line, Tumor/pathology , Drug Screening Assays, Antitumor , Female , Gene Expression Regulation, Neoplastic/drug effects , History, Ancient , Humans , Intestinal Neoplasms/drug therapy , Intestinal Neoplasms/genetics , Intestinal Neoplasms/metabolism , Intestinal Neoplasms/pathology , Male , Middle Aged , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , Protein Serine-Threonine Kinases/genetics , Protein Serine-Threonine Kinases/metabolism , Receptor, Transforming Growth Factor-beta Type II , Receptors, Transforming Growth Factor beta/genetics , Receptors, Transforming Growth Factor beta/metabolism , Wnt Signaling Pathway/drug effects , Wnt Signaling Pathway/genetics
17.
J Dig Dis ; 15(9): 469-76, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24957863

ABSTRACT

OBJECTIVE: We investigated whether the prokinetic activity of mosapride, a 5-hydroxytryptamine 4 receptor agonist, in combination with proton pump inhibitor (PPI) would ameliorate symptoms of gastroesophageal reflux disease (GERD) in Japanese patients. METHODS: Patients who experienced reflux symptoms more than twice weekly were eligible for this study. In all, 60 patients were randomized to receive mosapride 5 mg thrice daily combined with omeprazole 10 mg once daily (GO group), or omeprazole alone (O group) for 4 weeks. The patients completed the frequency scale for the symptoms of GERD (FSSG) at the beginning and the end of the study. The primary outcome compared changes in the FSSG reflux-related symptom (RS) score between treatment groups during the study period. RESULTS: The FSSG RS scores significantly decreased both in the GO group and the O group, with no differences in improvement between the groups (-5.86 for the GO group vs -4.89 for the O group, P = 0.49). In non-erosive reflux disease (NERD) patients the improvement was significantly lower than that in erosive GERD patients (-4.00 vs -7.67, P = 0.02). However, the addition of mosapride was effective in subgroup analyses of specific symptoms, such as burping. CONCLUSIONS: Combining mosapride with PPI provided no additional amelioration of reflux symptoms compared to PPI alone. Both regimens provided less relief from reflux symptoms in NERD than in erosive GERD patients. The addition of mosapride ameliorated reflux in patients with symptoms like burping.


Subject(s)
Benzamides/therapeutic use , Gastroesophageal Reflux/drug therapy , Gastrointestinal Agents/therapeutic use , Morpholines/therapeutic use , Omeprazole/therapeutic use , Proton Pump Inhibitors/therapeutic use , Aged , Benzamides/adverse effects , Drug Therapy, Combination , Female , Gastroesophageal Reflux/physiopathology , Gastrointestinal Agents/adverse effects , Gastrointestinal Motility/drug effects , Humans , Male , Middle Aged , Morpholines/adverse effects , Omeprazole/adverse effects , Prospective Studies , Proton Pump Inhibitors/adverse effects , Severity of Illness Index , Treatment Outcome
18.
Dig Liver Dis ; 46(10): 943-9, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24953207

ABSTRACT

BACKGROUND: Although both colorectal neoplasms and atherosclerosis may be induced by visceral fat accumulation, no association between these factors has yet been elucidated. METHODS: Among Japanese participants in our colonoscopic screening and annual surveillance programs, asymptomatic subjects were investigated. Visceral fat area was measured by computed tomography, and the ankle-brachial index and pulse-wave velocity (markers of systemic atherosclerosis) were also estimated. Colorectal findings during screening were investigated in association with these parameters. RESULTS: Nine hundred and seven subjects (males: 71.9%; mean age: 57.3±8.7 years) were enrolled. Colorectal adenomas were identified during colorectal screening of 407 subjects (44.9%). The prevalence of all colorectal adenoma and advanced neoplasia increased with an elevated pulse-wave velocity from 32.2% (advanced neoplasia, 2.6) to 62.1% (8.4%) in higher quartiles (p<0.001 and p=0.003). The risk of advanced neoplasia was higher in subjects with an abnormal ankle-brachial index (33% vs. 4.6%, p<0.001). Upon multivariate analysis, visceral fat area and pulse-wave velocity were associated with all adenoma, and the ankle-brachial index with advanced neoplasia. CONCLUSIONS: The risk of colorectal adenoma was strongly associated with visceral fat area and markers of atherosclerosis. Colorectal adenoma and atherosclerosis may share a common pathogenesis and the same populations are at high-risk.


Subject(s)
Adenoma/etiology , Ankle Brachial Index , Atherosclerosis/etiology , Colorectal Neoplasms/etiology , Intra-Abdominal Fat , Obesity, Abdominal/complications , Pulse Wave Analysis , Adenoma/diagnosis , Adult , Atherosclerosis/diagnosis , Body Mass Index , Colonoscopy , Colorectal Neoplasms/diagnosis , Early Detection of Cancer , Female , Humans , Logistic Models , Male , Middle Aged , Multivariate Analysis , Risk Factors , Waist Circumference
19.
J Clin Ultrasound ; 42(9): 554-6, 2014.
Article in English | MEDLINE | ID: mdl-24648312

ABSTRACT

To avoid retention of the capsule used in capsule endoscopy (CE), the patency capsule (PC), a self-disintegrating sham capsule, is administered prior to CE in patients suspected of small intestinal stenosis. If the PC is excreted intact within 30 hours of ingestion, the patient can undergo CE without retention. However, if the PC is not excreted within 30 hours, its location must be confirmed as in either the small intestine or the colon because of the potential for small intestinal stenosis in the former case. It is often difficult to confirm the location of the PC by abdominal radiograph. We report the case of one patient who did not excrete the PC within 30 hours and for whom it was difficult to distinguish whether the PC was in the small intestine or the colon on abdominal series. Abdominal sonography revealed the PC in the colon and subsequent CE was performed without complication.


Subject(s)
Capsule Endoscopy/instrumentation , Colon/diagnostic imaging , Foreign Bodies/diagnostic imaging , Aged , Humans , Male , Ultrasonography
20.
Gastrointest Endosc ; 80(1): 118-25, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24518124

ABSTRACT

BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) cause a high frequency of mucosal injuries in the small intestine. However, no reliable intervention, other than cessation of NSAIDs, has been established. OBJECTIVE: To evaluate whether irsogladine maleate reduces these injuries while continuing NSAID therapy. DESIGN: Prospective, interventional, endoscopist-blinded, randomized, controlled trial (RCT). SETTING: University hospital. PATIENTS: Patients regularly taking conventional NSAIDs for more than 4 weeks. INTERVENTIONS: We initially examined small-intestinal mucosal injuries by capsule endoscopy (CE) and screened participants for the RCT. In the RCT, patients with any mucosal injury were randomly assigned to the irsogladine group (4 mg/day) or the control group. MAIN OUTCOME MEASUREMENTS: The primary endpoint was the rate of mucosal injury improvement after 4 weeks of treatment monitored with a second CE. RESULTS: Sixty-one patients were evaluated with the first CE. Small intestine mucosal injuries were found in 41 patients (67.2%) and erosive or ulcerative lesions in 21 patients (34.4%). The injury prevalence was not different with gastroprotective drug treatment. Of 41 patients enrolled, 39 (19 patients in the irsogladine group and 20 in the control group) completed the study. The improvement rate was significantly higher in the irsogladine group (16/19 patients; 84.2%) than in the control group (9/20 patients; 45.0%; P = .02). LIMITATIONS: Asymptomatic lesions, single-institution data, and single-blind setting. CONCLUSION: Irsogladine maleate was effective for reducing NSAID-induced small-intestinal mucosal injury. (University Hospital Medical Information Network Clinical Trials Registry number UMIN000001507.).


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Anti-Ulcer Agents/therapeutic use , Intestinal Mucosa/pathology , Intestine, Small/pathology , Peptic Ulcer/drug therapy , Triazines/therapeutic use , Adult , Aged , Aged, 80 and over , Capsule Endoscopy , Female , Humans , Intestinal Mucosa/drug effects , Intestine, Small/drug effects , Male , Middle Aged , Peptic Ulcer/chemically induced , Prospective Studies , Single-Blind Method , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...